Latest:
Q&A: How Is Risankizumab’s FDA Approval Changing the Psoriatic Disease Landscape?
This Q&A highlights the significance of the FDA approval of risankizumab (Skyrizi) for psoriasis and psoriatic arthritis in pediatric patients.

OR WAIT null SECS
Latest:
Sonnenberg Breaks Down EMERGE Phase 3 Trial Design for DT120 in MDD